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Purpose:Wepresent a systematic screening for identifying associations between prescribed drugs and cancer risk
using the high quality Danish nationwide health registries.
Methods:We identiﬁed all patients (cases) with incident cancer in Denmark during 2000–2012 (n = 278,485)
and matched each case to 10 controls. Complete prescription histories since 1995 were extracted. Applying a
two-phased case–control approach, we ﬁrst identiﬁed drug classes or single drugs associated with an increased
or decreased risk of 99 different cancer types, and further evaluated potential associations by examining speciﬁc-
ity and dose–response patterns.
Findings: 22,125 drug–cancer pairs underwent evaluation in the ﬁrst phase. Of 4561 initial signals (i.e., drug–cancer
associations), 3541 (78%) failed to meet requirements for dose–response patterns and speciﬁcity, leaving 1020 el-
igible signals. Of these, 510 signals involved the use of single drugs, and 33% (166 signals) and 67% (344 signals)
suggested a reduced or an increased cancer risk, respectively.While a large proportion of the signals were attribut-
able to the underlying conditions being treated, our algorithm successfully identiﬁed well-established associations,
as well as several new signals that deserve further investigation.
Conclusion: Our results provide the basis for future targeted studies of single associations to capture novel carcino-
genic or chemopreventive effects of prescription drugs.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Identiﬁcation of unintended effects of drug therapy is an essential
part of post-marketing drug surveillance (pharmacovigilance), as
knowledge of rare side-effects is limited at the time of marketing of
new medications (Strom et al., 2012). Unintended effects of drugs
may involve an increase or a reduction in cancer risk (International
Agency for Research on Cancer, 2012; Umar et al., 2012). Although
systematic and comprehensive testing of genotoxicity and carcinoge-
nicity is performed for any new drug prior to marketing (Brambilla
and Martelli, 2009), both these laboratory assays and the premarketing
phase-3 trials are disadvantaged by the typically long latency period of
cancer development in humans (Umar et al., 2012; Burstein and
Schwartz, 2008). For example, the excess risk of breast cancer induced
by use of menopausal or contraceptive hormone therapy ﬁrst becomes
apparent after 5–10 years of continued use (Howell and Evans, 2011;
Zhu et al., 2012), and the protective effect of aspirin against colorectal
cancer requires at least ﬁve years of regular use (Chan et al., 2012;
Cuzick et al., 2015). Traditional approaches in pharmacovigilance
(based primarily on spontaneous reporting of adverse events) rarely
detect drug–cancer associations, primarily due to the long induction
time of most cancer types, which separate the use of the drug from the
diagnosis by several years. As most individual cancer types are rare and
have a long latency, pre-marketing clinical trials are unlikely to detect
carcinogenic or chemopreventive effects of drugs due to the typically
small size and short follow-up of these trials. Since neither spontaneous
reporting nor clinical trials would be effective in capturing signals, the
primary tool in surveillance of drugs for unintended carcinogenic or
cancer preventive effects would be analyses of large administrative
databases. Such studies have been instrumental in the identiﬁcation of
carcinogenic effects of several drugs, e.g., female hormone therapy and
phenacetin (International Agency for Research on Cancer, 2012).
Denmark has a long history of establishing nationwide health
care registries and databases with information on all Danish residents
(Thygesen and Ersbøll, 2014). Two of the nationwide registries with
the highest data quality, the Danish Prescription Registry (initiated
in 1995 (Kildemoes et al., 2011)) and the Danish Cancer Registry
(established in 1943 (Gjerstorff, 2011)), hold virtually complete data
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on drug prescriptions and incident cancer cases and thus provide a
unique setting for active surveillance of cancer risk associated with the
use of prescription drugs.
We established a system to screen for associations between prescrip-
tion drug use and cancer risk, based on amultiple case–control design. In
the present paper,we describe (i) the source population anddata sources,
(ii) the initial screening process, (iii) the strategy for internal validation
of signals, and (iv) initial results from the nationwide screening.
2. Setting and Data Sources
2.1. Data Sources
The entire Danish population is provided free tax-supportedmedical
care by the National Health Service (Thygesen and Ersbøll, 2014). For
administration and maintenance of this health care system, numerous
administrative and health registries have been established. In addition
to supporting high quality service in the health care system, these regis-
tries allow population-based studies covering all residents in Denmark
(approximately 5.6 millions).
The main data sources for our screening system include the Danish
Cancer Registry (Gjerstorff, 2011), the Danish Prescription Registry
(Kildemoes et al., 2011), the Danish National Patient Registry (Lynge
et al., 2011), and the Danish Civil Registration System (Pedersen, 2011).
The Danish Cancer Registry (Gjerstorff, 2011) has recorded incident
cancer cases on a nationwide basis since 1943 and has been shown to
have accurate and almost complete ascertainment of cases (Gjerstorff,
2011; Statens Serum Institute and Danish Cancer Society, n.d.). Approx-
imately 90% of cancer cases in the registry are histologically veriﬁed,
while the remaining are mainly represented by brain tumours and can-
cers in very old and/or frail patients. Cancer diagnoses are recorded
using the International Classiﬁcation of Diseases, version 10 (ICD-10),
and the ICD for Oncology (ICD-O-3).
The Danish National Prescription Registry (Kildemoes et al., 2011)
contains data on all prescription drugs dispensed to Danish residents
since 1995. The data include the type of drug, date of dispensing, and
quantity dispensed. Drugs are categorized according to the Anatomical
Therapeutic Chemical (ATC) index, a hierarchical classiﬁcation system
developed by the WHO (WHO Collaborating Centre for Drug Statistics
Methodology, 2014).
The Danish National Patient Register (Lynge et al., 2011) contains
nationwide data on all non-psychiatric hospital admissions since 1977
and all outpatient specialist contacts in hospital setting since 1995. Dis-
charge/contact diagnoses are coded using ICD-8 (1977–1993) and ICD-
10 (1994–).
The Danish Civil Registration System (Pedersen, 2011) contains data
on vital status (date of death) and migration to and from Denmark,
allowing sampling of general population controls and complete tracking
of study subjects.
2.2. Data Linkages
Data sourceswere linked by the civil registry number, a unique iden-
tiﬁer assigned to all Danish residents since 1968 (Pedersen, 2011).
Linkage was performed within Statistics Denmark, a governmental in-
stitution that collects andmaintains electronic records for a broad spec-
trum of statistical and scientiﬁc purposes (Thygesen et al., 2011a).
2.3. Identiﬁcation of Cancer Cases
From the Danish Cancer Registry, we identiﬁed all individuals in
Denmark with incident cancers diagnosed between January 1, 2000
and December 31, 2012. We deﬁned the index date as the date of diag-
nosis. Cases were restricted to histologically veriﬁed cancers (except for
tumours of the central nervous system, ofwhich someare based on clin-
ical and imaging ﬁndings only, and haematological malignancies).
Exclusion criteria were age outside 18–85 years at index date andmi-
gration to or from Denmark anytime during the 10 years prior to index
date. This ensured at least 10 years of complete follow-up prior to sam-
pling for all study subjects and a minimum of ﬁve years of prescription
data (available from 1995). We excluded the youngest since both drug
use and cancer incidence are low among children and adolescents. We
further excluded individuals with a previous history of cancer (except
non-melanoma skin cancer) thus focusing on primary incident cancers.
Based on ICD-O topography and morphology codes for 34 cancer
sites, we restricted the cancer outcomes to 99 cancer subtypes. For a
complete list of the included cancers and their deﬁnitions within the
Cancer Registry, see Appendix A.
2.4. Selection of Controls
Controls were selected using risk set sampling. For each case, we
randomly selected 10 controls from all Danish citizens applying the
same exclusion criteria as for cases and with the same sex and birth
year as the case. Controls were assigned an index date identical to that
of the corresponding case. Each subject was eligible for sampling as a
control before becoming a case and could be sampled as a control
more than once. Thereby, the calculated odds ratios (ORs) provide unbi-
ased estimates of the corresponding incidence rate ratios (IRRs) that
would have emerged from cohort studies conducted in the underlying
source population (Rothman et al., 2008).
2.5. Approvals and Funding
The study was approved by the Danish Data Protection Agency.
According to Danish law, studies based solely on register data do not re-
quire approval from an ethics review board (Thygesen et al., 2011a).
The study was funded by the Danish Council for Independent Research
(grant 4004-00234B). The funder had no role in the study conduct,
interpretation of data, or reporting of the ﬁndings.
3. Initial Screening Process
The process consisted of two stages. In the ﬁrst stage, we identiﬁed
potential signals, i.e., drug–cancer associations. Those associations
meeting our strength criteria qualiﬁed for further evaluation of causa-
tion in the second stage (see “Evaluation of Signals” below).
3.1. Classiﬁcation of Drug Exposures
For each cancer or cancer subtype in the screening process, we in-
cluded all drugs and drug classes that either had 10 observed long-
term users (deﬁned as ≥8 prescriptions) among the cases or where 10
cases were expected to be long-term users based on drug exposure
among the controls given no drug–cancer association. Single drugs
were deﬁned by the ﬁfth level of the ATC-system (e.g., C07AB02, meto-
prolol), and drug classes were analysed at both the second (e.g., C07, all
beta-blockers) and fourth level (e.g., C07AB, selective beta-blockers).
Exposure to a speciﬁc drug or drug class was assessed fromprescrip-
tion ﬁlls recorded in the Prescription Registry prior to the index date for
cases and controls. We classiﬁed use as non-use (0–1 prescription), in-
termediate use (2–7 prescriptions), and long-term use (≥8 prescrip-
tions). Eight prescriptions was chosen as a cut-off as drugs for chronic
treatment are typically supplied for 3 months use for each dispensing
in Denmark, whereby our deﬁnition of long-termusewould correspond
to two years' cumulative treatment.
In all assessments of primary drug exposures or confounders, we
disregarded prescriptions redeemed within one year prior to the
index date. This was done for two reasons. First, such recent exposure
is unlikely to be associated with cancer development (International
Agency for Research on Cancer, 2012; Umar et al., 2012). Secondly,
drug use has been shown to increase in the year prior to cancer
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diagnoses (Jørgensen et al., 2012), likely due to treatment of early
symptoms of yet undiagnosed cancers. Such treatment patterns raise
the possibility of reverse causation bias (Csizmadl et al., 2007).
3.2. First-level Screening
The analyses followed a conventionalmatched case–control approach
using conditional logistic regression. We estimated odds ratios (OR) for
each individual cancer outcome associated with the drug exposures by
comparing long-termuse (≥8ﬁlls) to non-use (i.e., disregarding interme-
diate use). Potential confounding by gender, age, and calendar time was
handled by the design (matching) and conditional analysis. We further
adjusted for Charlson Comorbidity Index (CCI) score (Charlson et al.,
1987; Thygesen et al., 2011b) (categorized as 0, 1, 2, 3 or 4+)using infor-
mation onmedical history recorded in the Patient Registry from 1977 up
to one year prior to index date, and years of schooling (categorized into
basic [≤10 years], short/medium [11–13 years], long [14+ years], or
missing) (Dalton et al., 2008).
All analyses were performed using Stata Release 13.0 (StataCorp,
College Station, TX, USA).
3.3. Deﬁnition of Signals
Following the initial analysis, we identiﬁed all drug–cancer pairs
meeting our criteria for strength of association. Signals were deﬁned
as drug–cancer associations with an OR greater than 1.5 or less than
0.67, or a lower limit of the 95% conﬁdence interval above 1.2 or a higher
limit below 0.83.
4. Evaluation of Signals
All signals identiﬁed in the initial screening procedure were
examined further according to two additional criteria: (i) speciﬁcity
and (ii) dose–response relationship.
4.1. Outcome Speciﬁcity
Signals were tested for speciﬁcity, i.e., whether the drug was associ-
ated with a particular cancer types or with cancer overall. No drug is
known to increase the risk of all cancer types, and absence of speciﬁcity
of the signals thus suggests the existence of bias, e.g., residual confound-
ing by smoking or other factors such as surveillance. In the test for spec-
iﬁcity of a given signal, we compared the point estimate for any drug–
cancer association with the particular drug's association with cancer
overall. To meet the criteria for speciﬁcity, we required that the ratio
of the OR for the signal to the overall OR was outside the range of
0.83–1.20.
4.2. Dose–Response Pattern
We tested each signal for presence of a dose–response relationship.
We ﬁrst restricted the data to ever-users of the drug of interest and then
estimated the incremental OR per prescription among the remaining
users, while capping exposure at 50 prescriptions. This incremental
OR corresponds to the slope of the dose–response curve. To evaluate
whether a dose–response relationship was present, we tested the null
hypothesis that the slope of the dose–response curve was zero. We
arbitrarily selected a cutoff of p b 0.10.
5. Results
Following exclusions, the ﬁnal study population consisted of
278,485 incident cancer cases. The most frequent cancers were ductal
adenocarcinoma of the breast among females (n = 36,805), prostate
adenocarcinoma among men (n= 34,443), and colon adenocarcinoma
in both genders (n = 24,557). In the initial screening process, 22,125
drug–cancer pairs underwent evaluation. For the majority of cancer
types (61 of 99),more than 100 drug–cancer pairs underwent evaluation.
A total of 4561 signals (i.e., drug–cancer pairs meeting criteria for
strength of association) were identiﬁed in the initial screening process,
most frequently for cancers of the lung (196 signals for squamous cell
carcinoma, 178 for small cell carcinoma and 176 for other adenocarci-
nomas). For ﬁve of the 99 cancer types, we found no signals in the initial
screening process (Table 1).
Of the signals identiﬁed in the initial screening stage, 3464 (75.9%)
failed to meet the criteria for dose–response relationship, 12 (0.2%)
failed the test for outcome speciﬁcity, while 65 (1.4%) failed both
criteria; thus leaving 1020 signals. The signals most commonly
disqualiﬁed because of the speciﬁcity criterion were drug–cancer pairs
involving squamous cell carcinoma of the pharynx and various types
of lung cancer. An overview of the total number of cases, drug–cancer
pairs undergoing evaluation, and ﬁnal signals are displayed in Table 1.
Of the ﬁnal 1020 signals, 159 were observed among drug classes at
the second level of the ATC-system, 351 among drug classes at the
fourth level, and 510 for single agents (ﬁfth level).
Table 2 displays all signals indicating a reduced cancer risk associat-
ed with long-term use of a drug class (at second ATC level), among as-
sociations based on more than 100 exposed cases or 1000 exposed
controls. Table 3 displays signals suggesting an increased risk with a
similar restriction. The full list of all 1020 signals for drug classes at
the second or fourth level of the ATC-system and for single drug sub-
stances are provided in Supplementary Results I–II, III–IV, and V–VI,
respectively.
6. Discussion
In this large-scale nationwide screening study, we evaluated 22,125
drug–cancer pairs and identiﬁed 1020 signals (i.e., drug–cancer associ-
ations) that met the criteria for strength of association, speciﬁcity, and
dose–response pattern. The majority of the identiﬁed signals (703 sig-
nals) indicated an increased cancer risk associatedwith the speciﬁc pre-
scription drugs, while a smaller proportion (317 signals) were inverse
associations indicative of a potential chemopreventive effect. Our ﬁnd-
ings constitute a broad basis for future comprehensive studies of signals
suggesting a potential causal relationship between the speciﬁc drugs
and cancer types. The public health importance of identifying carcino-
genic effects of drugs is evident, since even small carcinogenic effects
of widely used drugs will translate into numerous drug-induced cancer
cases. Moreover, neutral associations have important value by
reassuring prescribers and patients of the safety of drugs, which will
promote their appropriate use. Lastly, identiﬁcation of potential chemo-
preventive drug effectsmay provide a clue to development of new com-
pounds for cancer prophylaxis and treatment.
The primary strength of our study is the use of the Danish nation-
wide health registries, ensuring a prescription history of up to 17 years
and virtually complete ascertainment of cancer cases. The large study
population also allowed evaluation of drug exposure in relation to risk
of more rare cancers. The quality of the data in the Danish Prescription
Registry (Kildemoes et al., 2011) and the Danish Cancer Registry
(Gjerstorff, 2011) has been found to be high (Kildemoes et al., 2011;
Gjerstorff, 2011; Statens Serum Institute and Danish Cancer Society,
n.d.). Lastly, the detailed stratiﬁcation according to cancer histology
avoided lumping of cancer types with markedly different histology.
For example, lung cancer consists of squamous cell carcinoma, adeno-
carcinoma, small cell carcinoma, large cell carcinoma and carcinoids,
among others. As these cancer subtypes have markedly different biolo-
gy, it is unlikely that their development would be similarly affected by
the same drugs.
The principal weakness of the study is the lack of adjustment for
potential confounding from life-style factors. Although we adjusted for
education and a measure of comorbidity, our analyses would beneﬁt
from adjustment for life-style factors, such as obesity, alcohol
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Table 1
Overview of cancer cases and number of signals according to the screening phases, i.e., evaluation in the ﬁrst stage of the algorithm, initial screening, and the second stage, internal
validation.
No Cancer Cancer cases Drug–cancer pairs evaluated Signals passed stage 1 Signals passed stage 2
1 Lip (Squamous cell carcinoma) 491 113 19 3
2 Lip (Other) 31 0 0 0
3 Oral cavity (Squamous cell carcinoma) 3304 408 134 27
4 Oral cavity (Other) 272 63 19 1
5 Salivary glands (Adenocarcinoma) 368 77 15 2
6 Salivary glands (Other) 180 39 7 0
7 Pharynx (Squamous cell carcinoma) 3358 376 135 20
8 Pharynx (Other) 240 52 24 3
9 Oesophagus (Squamous cell carcinoma) 1889 296 101 24
10 Oesophagus (Adenocarcinoma) 1925 328 79 20
11 Oesophagus (Other) 412 107 25 7
12 Stomach (Adenocarcinoma) 4775 463 51 11
13 Stomach (Other) 412 97 15 2
14 Small intestine (Adenocarcinoma) 373 102 13 2
15 Small intestine (Carcinoid) 239 65 20 5
16 Small intestine (Other) 147 43 18 1
17 Colon (Adenocarcinoma) 24,557 809 66 14
18 Colon (Carcinoid) 386 84 9 1
19 Colon (Other) 283 77 15 4
20 Rectum (Adenocarcinoma) 13,445 654 94 21
21 Rectum (Other) 249 70 14 1
22 Liver (Hepatocellular carcinoma) 1382 301 121 39
23 Liver (Adenocarcinoma) 329 94 21 4
24 Liver (Bile duct carcinoma) 231 71 35 5
25 Liver (Other) 336 107 44 15
26 Gallbladder and biliary tract (Adenocarcinoma) 1129 253 46 13
27 Gallbladder and biliary tract (Bile duct carcinoma) 111 28 8 2
28 Gallbladder and biliary tract (Other) 128 49 18 3
29 Pancreas (Adenocarcinoma) 5522 500 64 10
30 Pancreas (Other) 1245 268 44 13
31 Larynx (Squamous cell carcinoma) 2630 351 110 20
32 Larynx (Other) 108 31 17 1
33 Lung (Adenocarcinoma) 14,363 707 176 55
34 Lung (Squamous cell carcinoma) 8526 619 196 66
35 Lung (Small cell carcinoma) 6745 564 178 62
36 Lung (Other (non-small cell)) 3829 444 125 31
37 Lung (Carcinoid) 783 198 66 14
38 Lung (Large cell carcinoma) 840 184 55 9
39 Lung (Other) 3609 436 113 30
40 Bones, joints and cartilage (Chondrosarcoma) 211 40 9 4
41 Bones, joints and cartilage (Osteosarcoma) 83 3 0 0
42 Bones, joints and cartilage (Ewing sarcoma) 42 0 0 0
43 Bones, joints and cartilage (Other) 82 4 3 0
44 Skin (Melanoma) 16,331 708 82 14
45 Skin (Other) 49 3 1 0
46 Mesothelium and connective tissue (Sarcomas) 1404 229 28 5
47 Mesothelium and connective tissue (Mesothelioma) 1125 206 38 7
48 Mesothelium and connective tissue (Other) 432 112 33 11
49 Breast (female) (Adenocarcinoma, Ductal carcinoma) 36,805 899 75 11
50 Breast (female) (Adenocarcinoma, other) 5275 525 58 14
51 Breast (female) (Adenocarcinoma, Lobular carcinoma) 5514 516 62 20
52 Breast (female) (Other) 723 178 27 1
53 Breast (male) (Other) 287 74 16 2
54 Vulva and vagina (Squamous cell carcinoma) 815 205 34 5
55 Vulva and vagina (Other) 225 79 18 3
56 Cervix uteri (Squamous cell carcinoma) 3208 354 96 23
57 Cervix uteri (Adenocarcinoma) 725 121 18 4
58 Cervix uteri (Other) 391 80 28 2
59 Corpus uteri (Adenocarcinoma, endometrioid) 5130 525 161 48
60 Corpus uteri (Adenocarcinoma, other) 940 208 52 7
61 Corpus uteri (Sarcomas) 574 147 37 8
62 Corpus uteri (Adenocarcinoma, serous) 420 131 39 7
63 Corpus uteri (Other) 538 138 42 4
64 Ovary (Adenocarcinoma, serous) 3002 396 62 18
65 Ovary (Adenocarcinoma, other) 916 231 38 6
66 Ovary (Adenocarcinoma, endometrioid) 527 117 21 4
67 Ovary (Adenocarcinoma, mucinous carcinoma) 482 101 20 5
68 Ovary (Adenocarcinoma, clear cell) 257 67 15 1
69 Ovary (Other) 591 141 32 2
70 Prostate (Adenocarcinoma) 34,443 800 126 34
71 Prostate (Other) 256 70 16 3
72 Testis (Seminoma) 2073 134 33 4
73 Testis (Teratoma) 586 21 5 1
74 Testis (Embryonal carcinoma) 468 17 9 0
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consumption, and smoking. However, this information is not available
in the Danish health registries. Moreover, a generic confounder adjust-
ment relevant to all cancers is difﬁcult as no universal confounders
exist, which emphasizes the need for tailored analyses of our individual
signals.
Under the null hypotheses and with the traditional α of 0.05, evalu-
ation of 22,000 associations is expected to result in approximately 1100
false positive associations. Importantly, this pertains to the initial signals
(n = 4561) before dose–response and speciﬁcity requirements. One
way to handle this would be to adjust for multiple testing, e.g.
Bonferroni correction (Rice et al., 2008). Although such adjustment re-
duces the number of false positive associations, it also reduces the like-
lihood that a true association will be captured. Given the explorative
nature of our screening study, we should not reject signals before they
can be subjected to rigorous evaluation. Thus, we did not include any
correction for multiple testing, as also recommended by others
(Rothman, 1990).
Some of the identiﬁed signals can be attributed to confounding by
indication. This is most notable for the observed associations with
lung cancers. As an example, drugs used to treat obstructive lung
diseases exhibited a strong association with squamous cell carcinoma
of the lung (OR, 2.61), which is likely explained by these drugs being
used for chronic obstructive pulmonary disease (COPD), which is
caused primarily by smoking (Supplementary Results I). Nevertheless,
our algorithm succeeded in identifying established or previously report-
ed associations, such as the association between use of female hormone
therapy and risk of ductal and lobular adenocarcinomas (International
Agency for Research on Cancer, 2007) (OR 1.92 and 2.65, respectively,
Supplementary Results V), and the association between the antihyper-
tensive drug hydrochlorothiazide and lip cancer (Friedman et al.,
Table 1 (continued)
No Cancer Cancer cases Drug–cancer pairs evaluated Signals passed stage 1 Signals passed stage 2
75 Testis (Choriocarcinoma) 109 1 0 0
76 Testis (Other) 99 1 0 0
77 Kidney (Adenocarcinoma, clear cell) 5083 496 120 21
78 Kidney (Adenocarcinoma, other) 385 105 31 7
79 Kidney (Other) 177 48 9 0
80 Renal pelvis and ureter (Urothelial carcinoma) 713 177 35 5
81 Renal pelvis and ureter (Other) 106 30 7 0
82 Bladder (Urothelial carcinoma) 7611 565 79 13
83 Bladder (Adenocarcinoma) 425 101 27 5
84 Bladder (Squamous cell carcinoma) 233 72 22 11
85 Bladder (Other) 277 90 20 4
86 Eye (Melanoma) 307 56 5 0
87 Eye (Other) 50 10 5 1
88 Brain and meninges (Glioma) 3669 391 55 15
89 Brain and meninges (Meningioma) 2045 307 51 10
90 Brain and meninges (Other) 653 104 17 5
91 Thyroidea (Adenocarcinoma, Papillary carcinoma) 1260 191 56 11
92 Thyroidea (Follicular carcinoma) 339 80 32 6
93 Thyroidea (Other) 399 91 18 6
94 Hodgkin (Other) 1346 184 59 8
95 Non-Hodgkin (Other) 9002 607 83 17
96 Multiple myeloma (Other) 3257 412 52 13
97 Leukaemia (Lymphatic) 3494 405 51 12
98 Leukaemia (Myeloid) 2719 354 55 5
99 Leukaemia (Other) 615 139 28 6
TOTAL 278,485 22,125 4561 1020
Table 2
16 signals (drug–cancer associations) indicative of a decreased cancer risk associatedwith drug classes at secondATC-level restricted to signalswithmore than100 long-termusers among
cancer cases or 1000 among controls for the given drug exposure.
Cancer ATC Drug class Cases
expo/nonexpo
Controls
expo/nonexpo
OR (95%CI)a Spec.b p⁎⁎⁎
Prostate (Adenocarcinoma) A06 Drugs for constipation 63/34,062 1987/337,637 0.33 (0.26–0.43) 0.73 0.01
Pharynx (Squamous cell carcinoma) C10 Lipid modifying agents 238/2953 3168/28,929 0.47 (0.40–0.54) 0.94 b0.01
Oral cavity (Squamous cell carcinoma) C10 Lipid modifying agents 274/2866 3092/28,577 0.56 (0.49–0.65) 0.94 0.03
Oral cavity (Squamous cell carcinoma) R01 Nasal preparations 78/3007 1244/29,426 0.58 (0.46–0.73) 0.97 b0.01
Lung (Other (non-small cell)) A10 Drugs used in diabetes 215/3571 2143/35,827 0.62 (0.53–0.72) 0.94 0.04
Lung (Adenocarcinoma) A10 Drugs used in diabetes 691/13,562 7415/134,978 0.63 (0.58–0.69) 0.94 0.09
Lung (Small cell carcinoma) D01 Antifungals for dermatological use 114/5849 1554/56,978 0.66 (0.54–0.80) 0.98 0.05
Larynx (Squamous cell carcinoma) C09 Agents acting on the renin–angiotensin system 384/2117 4370/20,674 0.66 (0.58–0.75) 1.01 0.06
Pharynx (Squamous cell carcinoma) C09 Agents acting on the renin–angiotensin system 419/2793 4572/27,633 0.67 (0.59–0.75) 1.01 0.05
Corpus uteri (Adenocarcinoma,
endometrioid)
R03 Drugs for obstructive airway diseases 344/4395 4732/42,762 0.72 (0.64–0.81) 1.16 b0.01
Lung (Small cell carcinoma) A10 Drugs used in diabetes 399/6262 3708/63,104 0.72 (0.64–0.81) 0.94 0.03
Cervix uteri (Squamous cell carcinoma) G03 Sex hormones and modulators of the genital system 1187/1692 13,254/14,514 0.73 (0.67–0.81) 1.12 b0.01
Prostate (Adenocarcinoma) N03 Antiepileptics 552/33,475 7698/332,407 0.74 (0.68–0.81) 1.01 b0.01
Lung (Squamous cell carcinoma) C09 Agents acting on the renin–angiotensin system 1589/6490 16,324/64,287 0.76 (0.72–0.81) 1.01 0.01
Rectum (Adenocarcinoma) N06 Psychoanaleptics 984/11,821 12,535/114,922 0.77 (0.71–0.82) 1.01 b0.01
Rectum (Adenocarcinoma) N02 Analgesics 1603/9929 19,197/94,719 0.78 (0.74–0.83) 1.06 b0.01
Notes: OR= odds ratio; CI = conﬁdence interval.
⁎⁎⁎ p-Value as obtained in the dose–response analysis.
a Adjusted for gender, age, and calendar time (by design) as well as Charlson Comorbidity Index (CCI) score and educational level.
b Speciﬁcity, i.e. the association (OR) between the drug and overall cancer risk.
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2012) (OR 6.93, Supplementary Results V). Such ﬁndings provide assur-
ance that our approach is capable of identifying true associations.
Some of the signals we have identiﬁed clearly warrant further inves-
tigation. For example, the two antibiotics pivmecillinamand sulfamethi-
zole displayed odds ratios of about 13 and 6, respectively, for squamous
cell carcinoma of the bladder (Supplementary Results V). Both drugs are
used speciﬁcally to treat urinary tract infections and, as such, this signal
might reﬂect a carcinogenic effect of inﬂammation due to recurrent
infections. However, as both drugs are designed to accumulate in the
bladder lumen and because the signalwas very strong, this signal should
be considered a candidate for future studies. Such studies should be
designed speciﬁcally for the individual drug–cancer association, by
Table 3
57 signals (drug–cancer associations) indicative of an increased cancer risk associated with drug classes at second ATC-level restricted to signals with more than 100 long-term users
among cancer cases or 1000 among controls for the given drug exposure.
Cancer ATC Drug class Cases
expo/nonexpo
Controls
expo/nonexpo
OR (95%CI)a Spec.b p⁎⁎⁎
Lung (Squamous cell carcinoma) R03 Drugs for obstructive airway diseases 1824/5947 7189/73,406 2.61 (2.45–2.78) 1.16 b0.01
Lung (Carcinoid) R03 Drugs for obstructive airway diseases 147/563 635/6679 2.43 (1.96–3.00) 1.16 0.09
Lung (Other (non-small cell)) R03 Drugs for obstructive airway diseases 680/2843 3194/32,806 2.08 (1.89–2.29) 1.16 0.02
Oesophagus (Adenocarcinoma) A02 Drugs for acid related disorders 366/1317 1976/15,268 2.07 (1.81–2.36) 1.07 b0.01
Pharynx (Squamous cell carcinoma) N05 Psycholeptics 771/2129 4096/26,149 2.07 (1.89–2.28) 1.08 b0.01
Liver (Hepatocellular carcinoma) A10 Drugs used in diabetes 301/1056 825/12,852 2.06 (1.72–2.46) 0.94 0.02
Lung (Other) R03 Drugs for obstructive airway diseases 618/2685 2951/30,893 2.03 (1.83–2.24) 1.16 b0.01
Vulva and vagina (Squamous cell carcinoma) D07 Corticosteroids, dermatological preparations 110/460 597/5457 1.99 (1.57–2.54) 1.02 b0.01
Hodgkin (Other) D07 Corticosteroids, dermatological preparations 106/910 629/9999 1.93 (1.53–2.43) 1.02 0.05
Oral cavity (Squamous cell carcinoma) N05 Psycholeptics 821/2030 4663/24,948 1.91 (1.73–2.10) 1.08 b0.01
Lung (Squamous cell carcinoma) L04 Immunosuppressants 149/8296 588/84,152 1.87 (1.55–2.25) 1.13 0.04
Lung (Adenocarcinoma) N07 Other nervous system drugs 228/13,549 1131/139,827 1.84 (1.59–2.13) 1.23 b0.01
Kidney (Adenocarcinoma, clear cell) C09 Agents acting on the renin–angiotensin system 1287/3484 8107/40,331 1.82 (1.68–1.96) 1.01 b0.01
Lip (Squamous cell carcinoma) C03 Diuretics 131/316 818/3662 1.80 (1.39–2.33) 1.05 b0.01
Larynx (Squamous cell carcinoma) N05 Psycholeptics 610/1704 3552/20,101 1.79 (1.61–1.99) 1.08 b0.01
Kidney (Adenocarcinoma, clear cell) C03 Diuretics 1147/3380 7528/39,297 1.78 (1.64–1.93) 1.05 0.05
Kidney (Adenocarcinoma, clear cell) C08 Calcium channel blockers 879/3878 5250/43,226 1.77 (1.63–1.93) 1.04 b0.01
Lung (Small cell carcinoma) R05 Cough and cold preparations 486/4974 2560/53,959 1.77 (1.59–1.97) 1.12 b0.01
Lung (Small cell carcinoma) P01 Antiprotozoals 180/6136 889/62,483 1.69 (1.43–1.99) 1.14 b0.01
Larynx (Squamous cell carcinoma) N02 Analgesics 505/1695 2866/19,793 1.68 (1.49–1.89) 1.06 b0.01
Liver (Hepatocellular carcinoma) N02 Analgesics 359/784 1658/10,175 1.67 (1.42–1.96) 1.06 b0.01
Lung (Squamous cell carcinoma) P01 Antiprotozoals 229/7765 1128/79,205 1.66 (1.43–1.93) 1.14 0.01
Stomach (Adenocarcinoma) A02 Drugs for acid related disorders 757/3397 4903/37,921 1.65 (1.51–1.81) 1.07 b0.01
Liver (Hepatocellular carcinoma) N05 Psycholeptics 373/823 2123/10,304 1.63 (1.40–1.89) 1.08 b0.01
Oral cavity (Squamous cell carcinoma) N02 Analgesics 677/2085 3912/24,711 1.63 (1.47–1.81) 1.06 b0.01
Lung (Adenocarcinoma) R03 Drugs for obstructive airway diseases 2100/11,087 11,905/122,450 1.63 (1.55–1.72) 1.16 b0.01
Breast (female) (Adenocarcinoma, Lobular
carcinoma)
G03 Sex hormones and modulators of the
genital system
2251/2622 16,711/31,474 1.62 (1.52–1.72) 1.12 b0.01
Lung (Squamous cell carcinoma) J01 Antibacterials for systemic use 2537/2401 17,597/30,244 1.62 (1.51–1.75) 1.16 b0.01
Pharynx (Squamous cell carcinoma) N03 Antiepileptics 134/3127 703/32,450 1.60 (1.32–1.95) 1.01 0.05
Lung (Squamous cell carcinoma) R05 Cough and cold preparations 580/6456 3195/68,899 1.60 (1.45–1.76) 1.12 b0.01
Lung (Carcinoid) J01 Antibacterials for systemic use 275/175 1987/2320 1.59 (1.25–2.01) 1.16 b0.01
Lung (Small cell carcinoma) J01 Antibacterials for systemic use 2038/1831 14,794/22,787 1.58 (1.46–1.72) 1.16 b0.01
Bladder (Adenocarcinoma) J01 Antibacterials for systemic use 114/111 856/1371 1.54 (1.12–2.13) 1.16 0.02
Lung (Squamous cell carcinoma) M05 Drugs for treatment of bone diseases 230/8172 1400/83,177 1.53 (1.32–1.77) 0.98 0.09
Lung (Small cell carcinoma) N02 Analgesics 1538/4,055 9975/47,049 1.53 (1.42–1.64) 1.06 b0.01
Lung (Adenocarcinoma) P01 Antiprotozoals 335/12,924 1928/132,006 1.49 (1.32–1.68) 1.14 b0.01
Corpus uteri (Adenocarcinoma, endometrioid) C03 Diuretics 1438/3135 11,378/34,576 1.48 (1.38–1.59) 1.05 b0.01
Lung (Adenocarcinoma) J01 Antibacterials for systemic use 4541/3,529 35,295/44,294 1.48 (1.40–1.56) 1.16 b0.01
Larynx (Squamous cell carcinoma) R05 Cough and cold preparations 131/2104 747/22,159 1.48 (1.21–1.80) 1.12 b0.01
Oesophagus (Squamous cell carcinoma) N05 Psycholeptics 410/1249 2936/13,955 1.47 (1.30–1.67) 1.08 0.03
Hodgkin (Other) J01 Antibacterials for systemic use 342/390 2679/4428 1.46 (1.20–1.78) 1.16 b0.01
Lung (Small cell carcinoma) N05 Psycholeptics 1752/4204 12,313/47,245 1.46 (1.37–1.55) 1.08 b0.01
Pharynx (Squamous cell carcinoma) N02 Analgesics 559/2255 3495/25,627 1.45 (1.30–1.62) 1.06 0.03
Lung (Squamous cell carcinoma) N02 Analgesics 1876/5158 12,176/60,203 1.45 (1.36–1.55) 1.06 b0.01
Corpus uteri (Adenocarcinoma, endometrioid) C09 Agents acting on the renin–angiotensin system 1055/3824 8204/40,669 1.45 (1.34–1.56) 1.01 b0.01
Liver (Hepatocellular carcinoma) M01 Antiinﬂammatory and antirheumatic products 342/615 2393/7353 1.43 (1.22–1.69) 1.04 0.04
Lung (Other (non-small cell)) J01 Antibacterials for systemic use 1127/1070 8380/13,046 1.43 (1.29–1.59) 1.16 b0.01
Leukaemia (Lymphatic) J01 Antibacterials for systemic use 836/1025 7235/12,145 1.40 (1.24–1.57) 1.16 0.04
Leukaemia (Myeloid) J01 Antibacterials for systemic use 698/822 5684/9407 1.39 (1.22–1.59) 1.16 b0.01
Breast (female) (Adenocarcinoma, Ductal
carcinoma)
G03 Sex hormones and modulators of the
genital system
14,170/18,036 117,211/201,628 1.37 (1.34–1.40) 1.12 b0.01
Lung (Adenocarcinoma) R05 Cough and cold preparations 864/10,808 5863/114,283 1.36 (1.26–1.47) 1.12 b0.01
Lung (Squamous cell carcinoma) N05 Psycholeptics 2063/5489 15,025/60,826 1.36 (1.29–1.44) 1.08 b0.01
Lung (Other (non-small cell)) N02 Analgesics 816/2388 5636/26,768 1.35 (1.22–1.48) 1.06 b0.01
Lung (Adenocarcinoma) N05 Psycholeptics 3435/9225 25,688/100,862 1.34 (1.28–1.40) 1.08 b0.01
Lung (Other (non-small cell)) N05 Psycholeptics 955/2406 7109/26,670 1.34 (1.23–1.46) 1.08 b0.01
Corpus uteri (Adenocarcinoma, endometrioid) C07 Beta blocking agents 781/4068 6331/42,068 1.32 (1.21–1.43) 0.99 b0.01
Lung (Adenocarcinoma) N02 Analgesics 2951/8915 21,622/99,702 1.32 (1.25–1.38) 1.06 b0.01
Notes: OR= odds ratio; CI = conﬁdence interval.
⁎⁎⁎ p-Value as obtained in the dose–response analysis.
a Adjusted for gender, age, and calendar time (by design) as well as Charlson Comorbidity Index (CCI) score and educational level.
b Speciﬁcity, i.e. the association (OR) between the drug and overall cancer risk.
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employing focused and comprehensive confounder adjustment and by
focusing on etiologically relevant exposure windows for the speciﬁc
cancer outcomes under study.
When decidingwhether a given drug–cancer association is worthy of
further study, i.e., prioritizing themany signals reported in this study, pa-
rameters other than the strength of the association should be considered.
Thought should be given to the potential for confounding by indication or
contraindication as discussed above, as well as biological plausibility,
e.g., by considering the pharmacological mechanism of the drug and/or
drawing upon ﬁndings in other studies, whether experimental, clinical
or observational. In addition, the potential public health impact of a puta-
tive association should be considered, as reﬂected by the number of at-
tributable cases, the aggressiveness of the cancer outcome and the age
of those affected. Finally, several drugs evaluated by the International
Agency for Research on Cancer (IARC) have been categorized as probably
(Group 2 A) or possibly (Group 2B) carcinogenic to humans, because ep-
idemiological evidence has not been deﬁnitive, or because carcinogenic-
ity has been demonstrated only in experimental animals (International
Agency for Research on Cancer, 2012; Friis et al., 2015). Additional
studies and continued monitoring of the potential carcinogenicity of
these drugs are of paramount importance.
Another valuable next step would be a full-scale replication of our
study, a common approach in, e.g., genome-wide screening studies
(NCI-NHGRI Working Group on Replication in Association Studies
et al., 2007). This would require access to data sources comparable to
the Danish registries, and should ideally hold data on potential life-
style confounders or health-seeking behaviour. The combined results
of the index and replication studies would help prioritize the signals
that warrant further research.
In conclusion, we have presented an approach for nationwide
screening of associations between the use of prescribed medications
and cancer risk. The results of this screening should undergo external
validation and the single drug–cancer associations should be subject
to tailored analysis, in order to enhance our understanding of carcino-
genic or chemopreventive effects of prescription drugs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.03.018.
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